• Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me
  KJA Associates, LLC - part-time CFO services

DURHAM, N.C., Aug. 6, 2019 /PRNewswire/ -- Emergo Therapeutics has successfully completed their Phase 2a trial for their novel candidate norketotifen (NKT).  The trial is yet another step forward in addressing the symptoms of the flu and flu-like illness.

The unique Phase 2a trial focused on using the immunomodulatory properties of NKT to treat symptoms associated with seasonal allergies.  As the cellular pathways that trigger symptoms in allergy and respiratory virus infection are very similar, Emergo elected to initially test NKT in an allergen challenge model to demonstrate NKT's efficacy.  Now that NKT has shown statistical significance in alleviating allergy symptoms—the next step is to demonstrate efficacy in community-based flu and flu-like illness.

Dr. Hazar Awad Granko, Emergo's Vice President of Drug Development and Regulatory Affairs, commented, "We are happy to continue our rapid progression through our clinical program around norketotifen.  The team has worked very hard to conduct patient-focused, high quality studies in a timely manner.  All of our efforts are now focused on initiating our Phase 2b trial in flu and flu-like illness in Q4 of this year."

About Emergo Therapeutics
Emergo Therapeutics (http://emergotherapeutics.com/) is focused on developing drugs that reduce inflammation and improve immune system function in various indications, starting with infectious diseases.  Emergo's lead program is the development of norketotifen for the treatment of uncomplicated influenza and influenza‑like illness (ILI).

Contact:
Henry (Hank) McCarthy II
Vice President, Business Development
Emergo Therapeutics, Inc.
6208 Fayetteville Road, Suite 104
Durham, NC 27713
+1 919 699 2197
​
SOURCE Emergo Therapeutics

Related Linkshttp://emergotherapeutics.com/
Powered by Create your own unique website with customizable templates.
  • Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me